United States: Is Next Generation Sequencing Ready For Personalized Medicine?

Next generation sequencing1 (NGS) promises to transform the delivery of health care by providing in one test diagnostic and prognostic information that had previously only been available in multiple analyses. One application of the information obtained from NGS is as a companion diagnostic for a therapeutic.2 A significant reduction in the overall cost to sequence the complete genome, most notably Illumina's announcement of the "$1,000 genome," makes NGS an attractive alternative to current locus-by-locus genetic analysis, and raises the prospect of near-term adoption of NGS in clinical medicine. This post will review some current opinions on NGS and whether the technology is ready for use in diagnostic and therapeutic development.

Translating Genomic-Based Research for Health

The potential for, and the challenges with, incorporating NGS into the co-development of targeted therapeutics and companion molecular tests was addressed in depth by a variety of stakeholders in Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop Summary (Workshop) and the findings summarized in its recently published report (Report).3

The Workshop was an outgrowth of the National Academies of Science's prior work regarding the establishment of clinical utility data for genomic technologies by the Academies' Roundtable on Translating Genomic-Based Research for Health.4 The Workshop was convened last year to examine and discuss potential solutions for the co-development of diagnostics and therapeutics. A wide range of perspectives were represented: patients, providers, clinical laboratories, the Food and Drug Administration (FDA), and payers.

A Regulatory Perspective

Elizabeth Mansfield, director of the personalized medicine staff in the Office of In Vitro Diagnostics and Radiologic Health at the FDA was a key participant representing a perspective on the regulatory challenges facing the use of NGS in diagnostic and therapeutic co-development. Dr. Mansfield remarked that the FDA understood the importance of NGS in clinical care and the opportunities it provides. In addition, but remarking on behalf of herself and not the FDA, she noted that "in the future, next-generation sequencing could report only mutations that have known drug safety or efficacy correlations,.. with additional data being retained for investigational use... As new information becomes available, new drugs could be approved, which would greatly increase the efficiency of the approval process."5 She added that however "even in co-development... not everyone who has [a particular] marker actually benefits from the drug. So we're still not there yet, even with next-generation sequencing."6

Patients, Providers and Laboratories

Representatives from these end users commented that NGS may solve some of the issues around cost and reimbursement that impede current diagnostic development. John Pfeifer, vice chair for clinical affairs, pathology and professor at Washington University School of Medicine stated that NGS could be the ultimate companion diagnostic but that several threshold issues need to be addressed prior to adoption, such as how to select the appropriate technology, how to improve reproducibility of the bioinformatics analysis, and how NGS would be regulated.7

Mark Robson, clinical director of the clinical genetics service in the Department of Human Genetics at Memorial Sloan-Kettering Cancer Center noted that Memorial Sloan-Kettering is currently using NGS where potential germline predispositions are difficult to define phenotypically.8 He remarked that NGS is useful for diseases that are due to a number of factors which are difficult to sort out and very expensive to test serially.

The Report noted an interesting observation with respect to cost. It may be assumed that because sequencing and analysis is accomplished for the complete genome at one time, NGS and its application should reduce health care costs. That is not necessarily true. Wylie Burke, professor and chair, Department of Bioethics and Humanities, University of Washington, noted that "while genomic technology could improve quality of care and reduce costs, it also has the potential to drive costs upward because there is a temptation to acquire as much data as possible...The health care system cannot afford to pay for all of the research that needs to be done to determine the utility of genomic information."9 Pfeifer observed other ways genomics can add costs, for example, tests being ordered for patients that are not well enough to benefit from the results.10

Payers and Regulators

Sharon Terry, president and chief executive officer of the Genetic Alliance, opined that NGS would provide unique regulatory and reimbursement challenges because it provides more information than just a single companion diagnostic. Joanne Armstrong, a senior medical director for Aetna, remarked that "when payers evaluate technologies, they do it individually. If a biomarker is safe, effective, and has clinical utility, it will be covered."11 However, with a panel of tests that contains multiple biomarkers, only those markers that have been shown to be safe, effective and useful will be covered by insurance.


The Report highlights the perspectives of stakeholders on whether NGS can be effectively integrated into the co-development of diagnosis and therapeutics. Similar to current technologies, the issues are complex and require coordination among numerous stakeholders as well as a clear regulatory pathway for development and application of the technology.


1 Next generation sequencing includes whole genome sequencing and whole exome sequencing.

2 IOM (Institute of Medicine) 2014. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop summary. Washington DC: The National Academies Press, at page 15.

3 IOM (Institute of Medicine) 2014. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests: Workshop summary. Washington DC: The National Academies Press, available at: http://www.nap.edu/catalog.php?record_id=18617.

4 Id. at 4.

5 Id. at 17.

6 Id. at 17.

7 Id. at 26.

8 Id. at 26.

9 Id. at 27.

10 Id. at 27.

11 Id. at 48.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions